Hanlon Investment Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Hanlon Investment Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.15M	Buy	7,272 +1,001	+16%	+$135K	0.61%	42
2026 Q1	$801K	Buy	+6,271	New	+$783K	0.44%	74

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Hanlon Investment Management's XBI Position: Q2 2026 in Review

Hanlon Investment Management increased its State Street SPDR S&P Biotech ETF (XBI) stake by 16% in Q2 2026, buying an estimated $135K and bringing the position to 7,272 shares worth $1.15M. The position accounts for 0.61% of the portfolio, ranked #42.

Hanlon Investment Management first reported a position in XBI in Q1 2026 and has held it in 2 quarters since. 932 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Hanlon Investment Management held 7,272 shares of State Street SPDR S&P Biotech ETF worth $1.15M as of Q2 2026.
Hanlon Investment Management bought 1,001 State Street SPDR S&P Biotech ETF shares in Q2 2026, an estimated $135K.
State Street SPDR S&P Biotech ETF made up 0.61% of Hanlon Investment Management's portfolio in Q2 2026, its #42 holding.
Hanlon Investment Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2026 and has held it in 2 quarters since.
932 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Hanlon Investment Management's 13F filing for Q2 2026, filed 31 Jul 2026.